Other studies have documented the cross-talk between FXR and PPARγ in alleviating liver fibrosis [49] and other metabolic diseases like nonalcoholic fatty liver disease [50]. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.